Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • January 16, 2025

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. PMID: 39817087; PMCID: PMC11734025.

Tags: amyloidosis, Cardiology/Epi, Outcomes, Publications, SGLT2 inhibitors, transthyretin amyloid cardiomyopathy

Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials

Ahmed M, Zulfiqar E, Ashraf H, Hashmi TM, Ahmed R, Rana JS, Greene SJ, Mentz RJ, Fudim M, Fonarow GC. Reduced-dose vs full-dose direct oral[...]

Sex Differences in Ketogenic Diet Response Reveal Gonadal Hormone Interaction With FGF21 in Mice

Zhang Y, Cochran JD, Souvenir RA, Tai W, Xia R, Gladwin BS, Barton NB, Pereira RO, Abel ED. Sex Differences in Ketogenic Diet Response Reveal[...]

Coronary Plaque Volume in an Asymptomatic Population: Miami Heart Study at Baptist Health South Florida

Ichikawa K, Ronen S, Bishay R, Krishnan S, Benzing T, Kianoush S, Aldana-Bitar J, Cainzos-Achirica M, Feldman T, Fialkow J, Budoff MJ, Nasir K. Coronary[...]